The company will use the capital to support ongoing clinical trials of its injectable Discogenic Cell Therapy (IDCT) for lumbar degenerative disc disease.
The company raises the funds through a non-brokered private placement. The proceeds will fund initiatives like securing FDA approval for clinical trials.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more